34/120
1.4 / 5 stars
All 120 Win/Lose results shown below
AXSM Roast Me summary
Axsome Therapeutics, Inc. (AXSM). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinAXSM / S&P 44.82% / 15.20% |
WinAXSM / S&P 56.87% / 15.00% |
LoseAXSM / S&P AXSM unavailable / 50.40% |
| 2026-Q11/3 |
LoseAXSM / S&P -7.46% / -4.33% |
WinAXSM / S&P 63.88% / 11.30% |
LoseAXSM / S&P AXSM unavailable / 27.70% |
| 2025-Q42/3 |
WinAXSM / S&P 50.38% / 2.65% |
WinAXSM / S&P 65.55% / 9.00% |
LoseAXSM / S&P AXSM unavailable / 13.40% |
| 2025-Q32/3 |
WinAXSM / S&P 16.34% / 8.12% |
WinAXSM / S&P 65.83% / 4.61% |
LoseAXSM / S&P AXSM unavailable / 13.45% |
| 2025-Q21/3 |
LoseAXSM / S&P -10.49% / 10.94% |
WinAXSM / S&P 69.83% / 4.83% |
LoseAXSM / S&P AXSM unavailable / 10.63% |
| 2025-Q12/3 |
WinAXSM / S&P 37.84% / -4.27% |
WinAXSM / S&P 72.16% / 4.98% |
LoseAXSM / S&P AXSM unavailable / 10.57% |
| 2024-Q41/3 |
LoseAXSM / S&P -5.85% / 2.41% |
WinAXSM / S&P 42.53% / 5.25% |
LoseAXSM / S&P AXSM unavailable / 6.15% |
| 2024-Q32/3 |
WinAXSM / S&P 11.64% / 5.89% |
WinAXSM / S&P 51.47% / 5.89% |
LoseAXSM / S&P AXSM unavailable / 6.11% |
| 2024-Q21/3 |
LoseAXSM / S&P 0.88% / 4.28% |
WinAXSM / S&P 59.73% / 5.38% |
LoseAXSM / S&P AXSM unavailable / 5.12% |
| 2024-Q11/3 |
LoseAXSM / S&P 0.26% / 10.56% |
WinAXSM / S&P 73.58% / 5.71% |
LoseAXSM / S&P AXSM unavailable / 5.59% |
| 2023-Q42/3 |
WinAXSM / S&P 13.88% / 11.69% |
WinAXSM / S&P 440.80% / 6.81% |
LoseAXSM / S&P AXSM unavailable / 7.78% |
| 2023-Q31/3 |
WinAXSM / S&P -2.74% / -3.27% |
LoseAXSM / S&P AXSM unavailable / 7.52% |
LoseAXSM / S&P AXSM unavailable / -5.03% |
| 2023-Q21/3 |
WinAXSM / S&P 16.50% / 8.74% |
LoseAXSM / S&P AXSM unavailable / 9.50% |
LoseAXSM / S&P AXSM unavailable / -8.57% |
| 2023-Q10/3 |
LoseAXSM / S&P -20.03% / 7.50% |
LoseAXSM / S&P AXSM unavailable / 10.77% |
LoseAXSM / S&P AXSM unavailable / -15.69% |
| 2022-Q41/3 |
WinAXSM / S&P 72.86% / 7.56% |
LoseAXSM / S&P AXSM unavailable / 11.88% |
LoseAXSM / S&P AXSM unavailable / -17.99% |
| 2022-Q31/3 |
WinAXSM / S&P 16.50% / -4.88% |
LoseAXSM / S&P AXSM unavailable / 13.47% |
LoseAXSM / S&P AXSM unavailable / -1.41% |
| 2022-Q21/3 |
WinAXSM / S&P -7.47% / -16.10% |
LoseAXSM / S&P AXSM unavailable / 13.71% |
LoseAXSM / S&P AXSM unavailable / 11.04% |
| 2022-Q11/3 |
WinAXSM / S&P 9.56% / -4.60% |
LoseAXSM / S&P AXSM unavailable / 15.97% |
LoseAXSM / S&P AXSM unavailable / 42.23% |
| 2021-Q41/3 |
WinAXSM / S&P 14.62% / 11.03% |
LoseAXSM / S&P AXSM unavailable / 15.00% |
LoseAXSM / S&P AXSM unavailable / 96.40% |
| 2021-Q30/3 |
LoseAXSM / S&P -51.14% / 0.58% |
LoseAXSM / S&P AXSM unavailable / 10.77% |
LoseAXSM / S&P AXSM unavailable / 69.42% |
| 2021-Q21/3 |
WinAXSM / S&P 19.15% / 8.55% |
LoseAXSM / S&P AXSM unavailable / 6.58% |
LoseAXSM / S&P AXSM unavailable / 51.81% |
| 2021-Q10/3 |
LoseAXSM / S&P -30.50% / 6.17% |
LoseAXSM / S&P AXSM unavailable / -1.06% |
LoseAXSM / S&P AXSM unavailable / 7.39% |
| 2020-Q41/3 |
WinAXSM / S&P 14.34% / 12.15% |
LoseAXSM / S&P AXSM unavailable / -3.72% |
LoseAXSM / S&P AXSM unavailable / -33.42% |
| 2020-Q30/3 |
LoseAXSM / S&P -13.41% / 8.93% |
LoseAXSM / S&P AXSM unavailable / -2.04% |
LoseAXSM / S&P AXSM unavailable / -27.10% |
| 2020-Q21/3 |
WinAXSM / S&P 39.86% / 20.54% |
LoseAXSM / S&P AXSM unavailable / -0.46% |
LoseAXSM / S&P AXSM unavailable / -27.11% |
| 2020-Q10/3 |
LoseAXSM / S&P -43.08% / -19.60% |
LoseAXSM / S&P AXSM unavailable / 3.47% |
LoseAXSM / S&P AXSM unavailable / -14.75% |
| 2019-Q41/3 |
WinAXSM / S&P 410.67% / 9.07% |
LoseAXSM / S&P AXSM unavailable / 5.36% |
LoseAXSM / S&P AXSM unavailable / 2.99% |
| 2019-Q30/3 |
LoseAXSM / S&P -21.40% / 1.70% |
LoseAXSM / S&P AXSM unavailable / 5.02% |
LoseAXSM / S&P AXSM unavailable / 0.21% |
| 2019-Q21/3 |
WinAXSM / S&P 80.96% / 4.30% |
LoseAXSM / S&P AXSM unavailable / 6.64% |
LoseAXSM / S&P AXSM unavailable / 8.65% |
| 2019-Q11/3 |
WinAXSM / S&P 404.61% / 13.65% |
LoseAXSM / S&P AXSM unavailable / 8.12% |
LoseAXSM / S&P AXSM unavailable / 14.29% |
| 2018-Q40/3 |
LoseAXSM / S&P -18.26% / -13.52% |
LoseAXSM / S&P AXSM unavailable / 9.05% |
LoseAXSM / S&P AXSM unavailable / 18.23% |
| 2018-Q31/3 |
WinAXSM / S&P 7.81% / 7.71% |
LoseAXSM / S&P AXSM unavailable / 10.21% |
LoseAXSM / S&P AXSM unavailable / 19.06% |
| 2018-Q21/3 |
WinAXSM / S&P 30.61% / 3.43% |
LoseAXSM / S&P AXSM unavailable / 9.03% |
LoseAXSM / S&P AXSM unavailable / 14.46% |
| 2018-Q10/3 |
LoseAXSM / S&P -56.25% / -0.76% |
LoseAXSM / S&P AXSM unavailable / 7.68% |
LoseAXSM / S&P AXSM unavailable / 12.46% |
| 2017-Q40/3 |
LoseAXSM / S&P 0.90% / 6.64% |
LoseAXSM / S&P AXSM unavailable / 7.03% |
LoseAXSM / S&P AXSM unavailable / 13.82% |
| 2017-Q30/3 |
LoseAXSM / S&P 0.91% / 4.48% |
LoseAXSM / S&P AXSM unavailable / 5.68% |
LoseAXSM / S&P AXSM unavailable / 17.57% |
| 2017-Q21/3 |
WinAXSM / S&P 41.03% / 3.09% |
LoseAXSM / S&P AXSM unavailable / 4.83% |
LoseAXSM / S&P AXSM unavailable / 17.74% |
| 2017-Q10/3 |
LoseAXSM / S&P -42.22% / 6.07% |
LoseAXSM / S&P AXSM unavailable / 3.67% |
LoseAXSM / S&P AXSM unavailable / 13.32% |
| 2016-Q40/3 |
LoseAXSM / S&P -14.34% / 3.82% |
LoseAXSM / S&P AXSM unavailable / 2.09% |
LoseAXSM / S&P AXSM unavailable / 7.05% |
| 2016-Q31/3 |
WinAXSM / S&P 4.51% / 3.85% |
LoseAXSM / S&P AXSM unavailable / 0.20% |
LoseAXSM / S&P AXSM unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | AXSM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 64.17% | 20.78% |
| Annualized return | 64.17% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | AXSM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 618.52% | 83.14% |
| Annualized return | 48.35% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | AXSM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 2646.23% | 319.30% |
| Annualized return | 39.28% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |